IceCure Study Shows 92.9% Volume Reduction in Breast Fibroadenomas with Cryoablation

Event summary

  • Independent study published in PLOS One demonstrates ProSense® cryoablation achieved 92.9% volume reduction of fibroadenomas one-year post-treatment.
  • Study included larger lesions and used multiple cryoprobe relocations, a first in this field.
  • ProSense® is FDA-cleared for fibroadenomas and could address approximately 63,000 cases annually in the U.S.
  • Research conducted at Premier Med Healthcare, Training, and Research Institute in Hungary.

The big picture

The study reinforces the safety and effectiveness of cryoablation for benign breast tumors, potentially shifting treatment paradigms away from surgical excision. This could expand IceCure's market reach, particularly as the technology gains traction in key markets where ProSense® is already used. The findings may also accelerate the adoption of minimally invasive procedures in breast health, aligning with broader trends toward less invasive medical treatments.

What we're watching

Guideline Impact
Whether the study's findings will influence treatment guidelines from medical societies like the American Society of Breast Surgeons.
Clinical Adoption
The pace at which minimally invasive cryoablation is adopted as an alternative to surgical excision for benign breast tumors.
Market Expansion
How IceCure can leverage these results to expand the use of ProSense® in other regions and for additional indications.

Related topics

Medical Devices